Cargando…

Divergent Evolution of Human p53 Binding Sites: Cell Cycle Versus Apoptosis

The p53 tumor suppressor is a sequence-specific pleiotropic transcription factor that coordinates cellular responses to DNA damage and stress, initiating cell-cycle arrest or triggering apoptosis. Although the human p53 binding site sequence (or response element [RE]) is well characterized, some gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Horvath, Monica M, Wang, Xuting, Resnick, Michael A, Bell, Douglas A
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1934401/
https://www.ncbi.nlm.nih.gov/pubmed/17677004
http://dx.doi.org/10.1371/journal.pgen.0030127
_version_ 1782134350620393472
author Horvath, Monica M
Wang, Xuting
Resnick, Michael A
Bell, Douglas A
author_facet Horvath, Monica M
Wang, Xuting
Resnick, Michael A
Bell, Douglas A
author_sort Horvath, Monica M
collection PubMed
description The p53 tumor suppressor is a sequence-specific pleiotropic transcription factor that coordinates cellular responses to DNA damage and stress, initiating cell-cycle arrest or triggering apoptosis. Although the human p53 binding site sequence (or response element [RE]) is well characterized, some genes have consensus-poor REs that are nevertheless both necessary and sufficient for transactivation by p53. Identification of new functional gene regulatory elements under these conditions is problematic, and evolutionary conservation is often employed. We evaluated the comparative genomics approach for assessing evolutionary conservation of putative binding sites by examining conservation of 83 experimentally validated human p53 REs against mouse, rat, rabbit, and dog genomes and detected pronounced conservation differences among p53 REs and p53-regulated pathways. Bona fide NRF2 (nuclear factor [erythroid-derived 2]-like 2 nuclear factor) and NFκB (nuclear factor of kappa light chain gene enhancer in B cells) binding sites, which direct oxidative stress and innate immunity responses, were used as controls, and both exhibited high interspecific conservation. Surprisingly, the average p53 RE was not significantly more conserved than background genomic sequence, and p53 REs in apoptosis genes as a group showed very little conservation. The common bioinformatics practice of filtering RE predictions by 80% rodent sequence identity would not only give a false positive rate of ∼19%, but miss up to 57% of true p53 REs. Examination of interspecific DNA base substitutions as a function of position in the p53 consensus sequence reveals an unexpected excess of diversity in apoptosis-regulating REs versus cell-cycle controlling REs (rodent comparisons: p < 1.0 e−12). While some p53 REs show relatively high levels of conservation, REs in many genes such as BAX, FAS, PCNA, CASP6, SIVA1, and P53AIP1 show little if any homology to rodent sequences. This difference suggests that among mammalian species, evolutionary conservation differs among p53 REs, with some having ancient ancestry and others of more recent origin. Overall our results reveal divergent evolutionary pressure among the binding targets of p53 and emphasize that comparative genomics methods must be used judiciously and tailored to the evolutionary history of the targeted functional regulatory regions.
format Text
id pubmed-1934401
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-19344012007-07-28 Divergent Evolution of Human p53 Binding Sites: Cell Cycle Versus Apoptosis Horvath, Monica M Wang, Xuting Resnick, Michael A Bell, Douglas A PLoS Genet Research Article The p53 tumor suppressor is a sequence-specific pleiotropic transcription factor that coordinates cellular responses to DNA damage and stress, initiating cell-cycle arrest or triggering apoptosis. Although the human p53 binding site sequence (or response element [RE]) is well characterized, some genes have consensus-poor REs that are nevertheless both necessary and sufficient for transactivation by p53. Identification of new functional gene regulatory elements under these conditions is problematic, and evolutionary conservation is often employed. We evaluated the comparative genomics approach for assessing evolutionary conservation of putative binding sites by examining conservation of 83 experimentally validated human p53 REs against mouse, rat, rabbit, and dog genomes and detected pronounced conservation differences among p53 REs and p53-regulated pathways. Bona fide NRF2 (nuclear factor [erythroid-derived 2]-like 2 nuclear factor) and NFκB (nuclear factor of kappa light chain gene enhancer in B cells) binding sites, which direct oxidative stress and innate immunity responses, were used as controls, and both exhibited high interspecific conservation. Surprisingly, the average p53 RE was not significantly more conserved than background genomic sequence, and p53 REs in apoptosis genes as a group showed very little conservation. The common bioinformatics practice of filtering RE predictions by 80% rodent sequence identity would not only give a false positive rate of ∼19%, but miss up to 57% of true p53 REs. Examination of interspecific DNA base substitutions as a function of position in the p53 consensus sequence reveals an unexpected excess of diversity in apoptosis-regulating REs versus cell-cycle controlling REs (rodent comparisons: p < 1.0 e−12). While some p53 REs show relatively high levels of conservation, REs in many genes such as BAX, FAS, PCNA, CASP6, SIVA1, and P53AIP1 show little if any homology to rodent sequences. This difference suggests that among mammalian species, evolutionary conservation differs among p53 REs, with some having ancient ancestry and others of more recent origin. Overall our results reveal divergent evolutionary pressure among the binding targets of p53 and emphasize that comparative genomics methods must be used judiciously and tailored to the evolutionary history of the targeted functional regulatory regions. Public Library of Science 2007-07 2007-07-27 /pmc/articles/PMC1934401/ /pubmed/17677004 http://dx.doi.org/10.1371/journal.pgen.0030127 Text en This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
spellingShingle Research Article
Horvath, Monica M
Wang, Xuting
Resnick, Michael A
Bell, Douglas A
Divergent Evolution of Human p53 Binding Sites: Cell Cycle Versus Apoptosis
title Divergent Evolution of Human p53 Binding Sites: Cell Cycle Versus Apoptosis
title_full Divergent Evolution of Human p53 Binding Sites: Cell Cycle Versus Apoptosis
title_fullStr Divergent Evolution of Human p53 Binding Sites: Cell Cycle Versus Apoptosis
title_full_unstemmed Divergent Evolution of Human p53 Binding Sites: Cell Cycle Versus Apoptosis
title_short Divergent Evolution of Human p53 Binding Sites: Cell Cycle Versus Apoptosis
title_sort divergent evolution of human p53 binding sites: cell cycle versus apoptosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1934401/
https://www.ncbi.nlm.nih.gov/pubmed/17677004
http://dx.doi.org/10.1371/journal.pgen.0030127
work_keys_str_mv AT horvathmonicam divergentevolutionofhumanp53bindingsitescellcycleversusapoptosis
AT wangxuting divergentevolutionofhumanp53bindingsitescellcycleversusapoptosis
AT resnickmichaela divergentevolutionofhumanp53bindingsitescellcycleversusapoptosis
AT belldouglasa divergentevolutionofhumanp53bindingsitescellcycleversusapoptosis